Targeted therapeutics
The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
1. A binding moiety-drug conjugate (SDC-TRAP) comprising a binding moiety and an effector moiety,
wherein the binding moiety is ganetespib,
wherein the effector moiety is gemcitabine or and
wherein the SDC-TRAP is selected from the group consisting of SDC-TRAP-309, SDC-TRAP-310, SDC-TRAP-311, SDC-TRAP-312, SDC-TRAP-313, SDC-TRAP-314, SDC-TRAP-315, SDC-TRAP-316, SDC-TRAP-317, SDC-TRAP-318, SDC-TRAP-319, SDC-TRAP-320, SDC-TRAP-321, SDC-TRAP-322, SDC-TRAP-323, SDC-TRAP-324, SDC-TRAP-325, SDC-TRAP-326, SDC-TRAP-327, SDC-TRAP-328, SDC-TRAP-329, SDC-TRAP-330, SDC-TRAP-331, SDC-TRAP-332, SDC-TRAP-333, and SDC-TRAP-334.
2. A pharmaceutical composition comprising a therapeutically effective amount of at least one SDC-TRAP of claim 1 , and at least one pharmaceutical excipient.
3. A kit for imaging, diagnosing, and/or selecting a subject comprising at least one SDC-TRAP of claim 1 and instruction for administering an effective amount of at least one SDC-TRAP of claim 1 to the subject, thereby imaging, diagnosing, and/or selecting the subject.
4. A method for treating a subject having a cancer comprising administering a therapeutically effective amount of at least one SDC-TRAP of claim 1 to the subject, thereby treating the cancer.
5. A method for treating a subject having chronic bronchitis comprising administering a therapeutically effective amount of at least one SDC-TRAP of claim 1 to the subject, thereby treating the chronic bronchitis.
6. A method for treating a subject having asthma comprising administering a therapeutically effective amount of at least one SDC-TRAP of claim 1 to the subject, thereby treating the asthma.
7. A method for treating a subject having actinic keratosis comprising administering a therapeutically effective amount of at least one SDC-TRAP of claim 1 to the subject, thereby treating the actinic keratosis.